Silence Therapeutics logo

SLN - Silence Therapeutics Share Price

421p -14.0  -3.2%

Last Trade - 25/11/20

Market Cap £360.8m
Enterprise Value £310.4m
Revenue £1.39m
Position in Universe 634th / 1800
Unlock SLN Revenue
Relative Strength (%)
1m +1.33%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.015 0.000 0.77 0.016 0.000 0.24 8.67 13.9 +74.7%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SilenceTherapeutics plc revenues increased from £0K to £1.1M. Netloss increased 34% to £11M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development costs increase from £5.1M to£10.2M (expense), Administrative expenses increase of 11%to £5.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SLN
Graphical History


SLN Revenue Unlock SLN Revenue

Net Income

SLN Net Income Unlock SLN Revenue

Normalised EPS

SLN Normalised EPS Unlock SLN Revenue

PE Ratio Range

SLN PE Ratio Range Unlock SLN Revenue

Dividend Yield Range

SLN Dividend Yield Range Unlock SLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SLN EPS Forecasts Unlock SLN Revenue
Profile Summary

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated November 18, 1994
Public Since January 5, 2010
No. of Shareholders: n/a
No. of Employees: 46
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 82,931,259
Free Float (0.0%)
Eligible for
SLN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SLN
Upcoming Events for SLN
Frequently Asked Questions for Silence Therapeutics
What is the Silence Therapeutics share price?

As of 25/11/20, shares in Silence Therapeutics are trading at 421p, giving the company a market capitalisation of £360.8m. This share price information is delayed by 15 minutes.

How has the Silence Therapeutics share price performed this year?

Shares in Silence Therapeutics are currently trading at 421p and the price has moved by -9.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Silence Therapeutics price has moved by 3.54% over the past year.

What are the analyst and broker recommendations for Silence Therapeutics?

Of the analysts with advisory recommendations for Silence Therapeutics, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Silence Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Silence Therapeutics next release its financial results?

Silence Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Silence Therapeutics dividend yield?

Silence Therapeutics does not currently pay a dividend.

Does Silence Therapeutics pay a dividend?

Silence Therapeutics does not currently pay a dividend.

When does Silence Therapeutics next pay dividends?

Silence Therapeutics does not currently pay a dividend.

How do I buy Silence Therapeutics shares?

To buy shares in Silence Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Silence Therapeutics?

Shares in Silence Therapeutics are currently trading at 421p, giving the company a market capitalisation of £360.8m.

Where are Silence Therapeutics shares listed? Where are Silence Therapeutics shares listed?

Here are the trading details for Silence Therapeutics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: SLN
What kind of share is Silence Therapeutics?

Based on an overall assessment of its quality, value and momentum, Silence Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Silence Therapeutics share price forecast 2020?

Shares in Silence Therapeutics are currently priced at 421p. At that level they are trading at 0.109% discount to the analyst consensus target price of 421.46.

Analysts covering Silence Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.29143 for the next financial year.

How can I tell whether the Silence Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Silence Therapeutics. Over the past six months, the relative strength of its shares against the market has been -11.4%. At the current price of 421p, shares in Silence Therapeutics are trading at -0.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Silence Therapeutics PE Ratio?

We were not able to find PE ratio data for Silence Therapeutics.

Who are the key directors of Silence Therapeutics?

Silence Therapeutics's management team is headed by:

Alistair Gray - NID
David Lemus - NED
iain Ross - NEC
James Ede-Golightly - NED
Steven Romano - NED
Robert Quinn - CFO
Mark Rothera - PRE
Who are the major shareholders of Silence Therapeutics?

Here are the top five shareholders of Silence Therapeutics based on the size of their shareholding:

Griffiths (Richard Ian) Individual Investor
Percentage owned: 27.4% (22.7m shares)
Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 12.77% (10.6m shares)
Quested (Robert) Individual Investor
Percentage owned: 7.17% (5.95m shares)
Cache Holdings Ltd. Corporation
Percentage owned: 6.1% (5.06m shares)
AstraZeneca (UK) Ltd. Corporation
Percentage owned: 5.3% (4.40m shares)
Similar to SLN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.